GGrantIndex
Sort

82,697 grants matching vaccine development

Vaccines and Therapeutics for Anthrax

$1,066,759
Stephen Leppla · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI

Viral/Immune parameters of Dengue and WNV in donors: blood safety implications

$1,066,706
Michael Paul Busch · Vitalant · RC2 · FY2010 · HL

Center of Excellence for High Throughput Proteogenomic Characterization

$1,066,337
Steven A. Carr · Broad Institute, Inc. · U24 · FY2023 · CA

Eliciting VRC01-like bNAbs by Specifically Designed Env Immunogens

$1,066,201
Leonidas A Stamatatos · Fred Hutchinson Cancer Research Center · U19 · FY2014 · AI

Task D04:World Reference Center for Emerging Viruses and Arboviruses

$1,065,853
Alan D.t. Barrett · University Of Texas Med Br Galveston · N01 · FY2014 · AI

Development of botulinum neurotoxin immunotherapy

$1,065,728
University Of California San Francisco · U01 · FY2005 · AI

Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure

$1,065,423
Sharon Riddler · University Of Pittsburgh At Pittsburgh · U01 · FY2017 · AI

Project 1: Immunization strategies to elicit broadly neutralizing antibodies against HIV-1

$1,065,397
Pamela J Bjorkman · California Institute Of Technology · P01 · FY2021 · AI

Functional genomic analysis of the CD8 T cell response to HIV vaccines in

$1,065,338
William Nicholas Haining · Dana-Farber Cancer Inst · R01 · FY2011 · AI

Role of inflammation, innate resistance, and immunity in carcinogenesis.

$1,065,311
Giorgio Trinchieri · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA

NINDS/UC Davis NeuroMab Hybridoma Facility

$1,064,984
James S Trimmer · University Of California At Davis · U24 · FY2007 · NS

Preclinical Studies of Bunyaviruses

$1,064,872
Kanta Subbarao · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI

SMALL MOLECULE SCREENING TO IDENTIFY INHIBITORS OF FILOVIRAL

$1,064,841
Arnab Basu · Icahn School Of Medicine At Mount Sinai · U19 · FY2016 · AI

Task V06: Immunogenicity and efficacy testing of COVID-19 vaccine candidates in nonhuman primates

$1,064,710
Thomas Rudge · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2021 · AI

New Approaches To Passive Immunoprophylaxis

$1,064,532
Robert H. Purcell · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI

Profiling cancer neoantigen repertoires and validating immunotherapy targets

$1,064,486
Martin W McIntosh · Fred Hutchinson Cancer Research Center · U01 · FY2016 · CA

Project-002

$1,064,411
Arnab Basu · Georgia State University · U19 · FY2017 · AI

SBIR Phase II: Development of Polymer Gel-Based Indicators to Monitor the Exposure of Shipments of Pharmaceuticals to Harmful Temperatures

$1,063,975
Bani H Cipriano · Prasidiux Llc · · FY2014 · TIP

Resource for NMR Molecular Imaging of Proteins

$1,063,830
University Of California San Diego · P41 · FY2004 · EB

Papillomavirus Virion Proteins and Vaccines

$1,063,732
Douglas R. Lowy · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Omics, Bioinformatics, and Data Management Core

$1,063,373
Michael J Gale · Oregon Health & Science University · P01 · FY2022 · AI

Development of Enabling Vector/Antigen Expression Technology for an Orally-Delive

$1,063,088
B. Kim Lee Sim · Protein Potential, Llc · R01 · FY2013 · AI

CENTER FOR COMPUTATIONAL MASS-SPECTROMETRY

$1,062,982
Pavel A Pevzner · University Of California, San Diego · P41 · FY2010 · RR

Center for Computational Mass-Spectrometry

$1,062,982
Pavel A Pevzner · University Of California, San Diego · P41 · FY2010 · RR

Immunity to Pneumonic Tularemia

$1,062,784
Catharine Bosio · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI